Navigation Links
YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Date:12/10/2009

and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, rare incidents of Grade IV radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not l
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Biosciences Acquires Protein Forest
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
4. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
5. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
6. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
7. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
9. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
10. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Sterlitech is proud to announce that ... stable of products . These additional products ... include membrane filters with surface charges. , ... for our membrane process testing equipment, and correspondingly, a ... membranes,” explains Sterlitech President Mark Spatz. “The addition ...
(Date:8/28/2014)... work by a Florida State University research team has ... your temperature, emit white light, and convert photon energy ... like a butterfly. , Biwu Ma, associate professor in ... FAMU-FSU College of Engineering, created the molecule in a ... discover that his creation has many other unique capabilities. ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
Breaking Biology Technology:Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2
... Inc. (Nasdaq: SRLS ) will release its fiscal ... on Friday, February 11, 2011. SeraCare executives will host a ... day to review first quarter results. The ... can be accessed by logging on to the "Investor Center, ...
... Inc. (Nasdaq: PCYC ) today reported recent ... that ended December 31, 2010.Recent Developments & Highlights ... PCI-32765 in B-cell malignanciesPharmacyclics has designed a broad Phase ... and diffuse large B-cell lymphoma to inform the Phase ...
... new way of splitting layered materials to give atom ... a range of novel two-dimensional nanomaterials with chemical and ... electronic and energy storage technologies. The collaborative* international ... Nanostructures and Nanodevices (CRANN), Trinity College Dublin, Ireland, and ...
Cached Biology Technology:Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 3Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 4Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 5Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 6Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 7Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 8Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 9New nanomaterials unlock new electronic and energy technologies 2
(Date:9/1/2014)... increasing amount of research shows an association between TV ... lifestyle. Now, a new Cornell University study points out ... might lead people to eat twice as much as ... action movie while snacking your mouth will see more ... the new article just published in the Journal ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... U.S. diet showed some modest improvement in the last ... the consumption of unhealthy trans fats, but the gap ... the poor. , , An unhealthy diet is closely ... a healthy diet is an important part of the ... in diet quality is important because it can offer ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... This press release is available in ... packaging mealworms infected with beneficial nematodes could improve the ... biological control agents. The machine is the result ... Department of Agriculture (USDA) scientists and Southeastern Insectaries, Inc., ...
... CitiusTech announced today that its BI-Clinical platform ... ACO quality measures that are part of the ACO ... BI-Clinical can now help ACO participants assess ... four domains - patient / caregiver experience, care coordination ...
... trial was random, regulated, double-blinded and broad-based. The drug was ... with Type 1 diabetes a short time before joining the ... in Europe, Israel and South Africa. The patients in the ... received the trial drug (DiaPep277) through a subcutaneous injection once ...
Cached Biology News:Special delivery: Nematode-infected insect cadavers 2BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS 2Andromeda Biotech: A drug for type 1 diabetes 2
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... Kit is one of the most ... of RNA in solution. The ... than absorbance measurements. As little as ... fluorescence microplate readers and fluorometers using ...
... The GenoStat Inducible Expression System provides tightly ... mammalian cells and is capable of repeated ... is mediated by the highly specific interaction ... bipartite nuclear receptor complex. Gene expression levels ...
Biology Products: